Advancing an Organizational Health Perspective for Insider Threat Prevention and Management

Malicious insiders pose a serious risk to valued organizational assets, including proprietary information, institutional processes, personnel, finances, reputation, and firm connections. Research-based solutions for predicting, detecting, and mitigating insider threats have focused heavily on individual, organizational, and cyber risk factors (Kont et al. 2015; Greitzer et al. 2018). To that end, scholars have increasingly recognized that people’s personalities, motivations, grievances, and work stressors raise the risk of insider threat events, and the corresponding interventional strategies involve cybersecurity and work design practices to safeguard the organization against human error and deviance (Homoliak et al. 2019; Greitzer et al. 2013; Maasberg, Warren, and Beebe 2015). Yet, despite evidence that insider threat events are perpetrated by people situated within a social and organizational context, discussions of insider threat have only started to recognize the importance of socio-organizational protective factors for reducing the occurrence of insider threats (Moore, Gardner, and Rousseau 2022; Whitty 2021). We argue that a healthy organization—an organization whose people, practices, and policies effectively sustain its survival and performance—may be key to preventing and managing insider threats

Organotypic Brain Cultures for Metastasis Research

We thank members of Brain Metastasis Group for critical discussion. Research in the Brain Metastasis Group is supported by MINECO-Retos SAF2017-89643-R (M.V.), Cancer Research Institute CLIP Award 2018 (M.V.), AECC (GCTRA16015SEOA) (M.V.), Bristol-Myers Squibb Melanoma Research Alliance Young Investigator Award 2017 (M.V.), Beug Foundation’s Prize for Metastasis Research 2017 (M.V.), Worldwide Cancer Research (19-0177) (M.V.), H2020-FETOPEN (828972) (M.V.), Fundación Ramón Areces (CIVP19S8163), and La Caixa-Severo Ochoa International PhD Program Fellowship (L.Z.). M.V. is a Ramón y Cajal Investigator (RYC-2013-13365) and an EMBO YIP investigator.N

Time-varying correlation between oil and stock market volatilities: Evidence from oil-importing and oil-exporting countries

This paper investigates the time-varying conditional correlation between oil price and stock market volatility for six major oil-importing and oil-exporting countries. The period of the study runs from January 2000 until December 2014 and a Diag-BEKK model is employed. Our findings report the following regularities. (i) The correlation between the oil and stock market volatilities changes over time fluctuating at both positive and negative values. (ii). Heterogeneous patterns in the time-varying correlations are evident between the oil-importing and oil-exporting countries. (iii) Correlations are responsive to major economic and geopolitical events, such as the early-2000 recession, the 9/11 terrorist attacks and the global financial crisis of 2007-2009. These findings are important for risk management practices, derivative pricing and portfolio rebalancing

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

Search for the standard model Higgs boson produced in association with W and Z bosons in pp collisions at √s=7 TeV

This is the pre-print version of the Article. The official published version can be accessed from the link below - Copyright @ 2012 Springer Verlag.A search for the Higgs boson produced in association with a W or Z boson in proton-proton collisions at a center-of-mass energy of 7 TeV is performed with the CMS detector at the LHC using the full 2011 data sample, from an integrated luminosity of 5 fb−1. Higgs boson decay modes to ττ and WW are explored by selecting events with three or four leptons in the final state. No excess above background expectations is observed, resulting in exclusion limits on the product of Higgs associated production cross section and decay branching fraction for Higgs boson masses between 110 and 200 GeV in these channels. Combining these results with other CMS associated production searches using the same dataset in the H→ γγ and H→ bb− decay modes, the cross section for associated Higgs boson production 3.3 times the standard model expectation or larger is ruled out at the 95% confidence level for a Higgs boson mass of 125 GeV.This study is funded by the BMWF and FWF (Austria); FNRS and FWO (Belgium); CNPq, CAPES, FAPERJ, and FAPESP (Brazil); MES (Bulgaria); CERN; CAS, MoST, and NSFC (China); COLCIENCIAS (Colombia); MSES (Croatia); RPF (Cyprus); MoER, SF0690030s09 and ERDF (Estonia); Academy of Finland, MEC, and HIP (Finland); CEA and CNRS/IN2P3 (France); BMBF, DFG, and HGF (Germany); GSRT (Greece); OTKA and NKTH (Hungary); DAE and DST (India); IPM (Iran); SFI (Ireland); INFN (Italy); NRF and WCU (Korea); LAS (Lithuania); CINVESTAV, CONACYT, SEP, and UASLP-FAI (Mexico); MSI (New Zealand); PAEC (Pakistan); MSHE and NSC (Poland); FCT (Portugal); JINR (Armenia, Belarus, Georgia, Ukraine, Uzbekistan); MON, RosAtom, RAS and RFBR (Russia); MSTD (Serbia); SEIDI and CPAN (Spain); Swiss Funding Agencies (Switzerland); NSC (Taipei); ThEP, IPST and NECTEC (Thailand); TUBITAK and TAEK (Turkey); NASU (Ukraine); STFC (United Kingdom); DOE and NSF (USA)

Search for the standard model Higgs boson produced in association with W and Z bosons in pp collisions at root s=7 TeV

A search for the Higgs boson produced in association with a W or Z boson in proton-proton collisions at a center-of-mass energy of 7 TeV is performed with the CMS detector at the LHC using the full 2011 data sample, from an integrated luminosity of 5 fb−1. Higgs boson decay modes to ττ and WW are explored by selecting events with three or four leptons in the final state. No excess above background expectations is observed, resulting in exclusion limits on the product of Higgs associated production cross section and decay branching fraction for Higgs boson masses between 110 and 200 GeV in these channels. Combining these results with other CMS associated production searches using the same dataset in the H→ γγ and H→ b b¯ decay modes, the cross section for associated Higgs boson production 3.3 times the standard model expectation or larger is ruled out at the 95% confidence level for a Higgs boson mass of 125 GeV

Peptide Nucleic Acids Synthesis and Analysis

Peptide nucleic acids (PNAs) are oligonucleotide analogues with the sugar-phosphate backbone replaced by the pseudopeptide skeleton, functioning as antigene/antisense chemical agents, initially designed by Nielson and coworkers. PNAs used the natural nucleobases to form hybridization by the Watson-Crick base pairing. This project focuses on the synthesis and optimization of 11mer PNA attracted to a protein

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors

Purpose: PI-88 is a mixture of highly sulfated oligosaccharides that inhibits heparanase, an extracellular matrix endoglycosidase, and the binding of angiogenic growth factors to heparan sulfate. This agent showed potent inhibition of placental blood vessel angiogenesis as well as growth inhibition in multiple xenograft models, thus forming the basis for this study. Experimental Design: This study evaluated the toxicity and pharmacokinetics of PI-88 (80-315 mg) when administered s.c. daily for 4 consecutive days bimonthly (part 1) or weekly (part 2). Results: Forty-two patients [median age, 53 years (range, 19-78 years); median performance status, 1] with a range of advanced solid tumors received a total of 232 courses. The maximum tolerated dose was 250 mg/d. Dose-limiting toxicity consisted of thrombocytopenia and pulmonary embolism. Other toxicity was generally mild and included prolongation of the activated partial thromboplastin time and injection site echymosis. The pharmacokinetics were linear with dose. Intrapatient variability was low and interpatient variability was moderate. Both AUC and C-max correlated with the percent increase in activated partial thromboplastin time, showing that this pharmacodynamic end point can be used as a surrogate for drug exposure, No association between PI-88 administration and vascular endothelial growth factor or basic fibroblast growth factor levels was observed. One patient with melanoma had a partial response, which was maintained for >50 months, and 9 patients had stable disease for >= 6 months. Conclusion: The recommended dose of PI-88 administered for 4 consecutive days bimonthly or weekly is 250 mg/d. PI-88 was generally well tolerated. Evidence of efficacy in melanoma supports further evaluation of PI-88 in phase II trials